

8 January 2026

## Treatment for HIV

- 1. How many patients were treated in the last 6-month period with branded or generic emtricitabine / tenofovir disoproxil fumarate (Truvada) for HIV treatment?**

For the 6 month period (June to November 2025) there were 0 patients treated with branded emtricitabine / tenofovir disoproxil fumarate (Truvada) for HIV treatment. In the same period there were 201 patients treated with generic emtricitabine / tenofovir disoproxil fumarate for HIV treatment (this figure is regional, covering all Trusts. It is not possible to determine from the data if Emergency Department figures are included in this figure.

- 2. How many patients were treated in the last 6-month period with branded or generic emtricitabine / tenofovir disoproxil fumarate for Pre-exposure prophylaxis (PrEP)?**

For the 6 month period (June to November 2025) there were 677 patients treated with branded or generic emtricitabine / tenofovir disoproxil fumarate for Pre-exposure prophylaxis (PrEP).

Please note that this information may be an underestimate due to some coding differences within the data source.

- 3. How many packs of branded or generic emtricitabine / tenofovir disoproxil fumarate were dispensed in latest 6-month period for HIV treatment?**

6 month period: June – November 2025

Pack description: EMTRICITABINE 200MG AND TENOFOVIR DISOPROXIL 245MG FILM COATED TABLETS, 30 tablet, pack, PACK OF 1

Total packs dispensed from pharmacy = 702

- 4. How many packs of branded or generic emtricitabine / tenofovir disoproxil fumarate were dispensed in latest 6-month period for Pre-exposure prophylaxis (PrEP)?**

6 month period: June – November 2025

Over-labelled packs supplied to clinic as bulk/inventory for onward supply to patients.

Pack description: EMTRICITABINE 200MG AND TENOFOVIR DISOPROXIL 245MG (PrEP) FILM COATED TABLETS, 30 tablet, overlabel pack, PACK OF 1

Total over-labelled packs supplied to clinic = 3150

8 January 2026

**5. How many patients were treated in the last 6-month period with tenofovir alafenamide / emtricitabine (Descovy) for HIV treatment?**

For the 6 month period (June to November 2025) there were 88 patients treated with tenofovir alafenamide / emtricitabine (Descovy) for HIV treatment.

Please note that the Trust have relied on a regional data source for this information so this data includes all five Trusts. This data does not include other combination regimens that contain FTC/TAF

**6. How many patients were treated in the last 6-month period with tenofovir alafenamide / emtricitabine for Pre-exposure prophylaxis (PrEP)?**

For the 6 month period (June to November 2025) there were 3 patients treated with tenofovir alafenamide / emtricitabine for Pre-exposure prophylaxis (PrEP).

Please note that this information may be an underestimate due to some coding differences within the data source.

**7. How many packs of tenofovir alafenamide / emtricitabine were dispensed in latest 6-month period for HIV treatment?**

6 month period: June – November 2025  
Pack description: EMTRICITABINE 200MG AND TENOFOVIR ALAFENAMIDE 25MG TABLETS, 30 tablet, pack, PACK OF 1  
Total packs dispensed from pharmacy: 323

**8. How many packs of tenofovir alafenamide / emtricitabine were dispensed in latest 6-month period for Pre-exposure prophylaxis (PrEP)?**

6 month period: June – November 2025  
Pack description: EMTRICITABINE 200MG AND TENOFOVIR ALAFENAMIDE 25MG TABLETS (PREP), 30 Tablet, Pack, and PACK OF 1  
Total packs dispensed from pharmacy: 6